We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




GE Healthcare To Acquire Whatman

By Biotechdaily staff writers
Posted on 12 Feb 2008
GE Healthcare (Chalfont St. More...
Giles, UK), a unit of General Electric Co., and Whatman plc (Maidstone, UK) have reached agreement on the terms of a recommended acquisition of Whatman by GE Healthcare.

Under the terms of the transaction, each Whatman shareholder will receive GBP 2.70 in cash for each Whatman share, valuing Whatman at approximately GBP 363 million. The transaction is subject to shareholder as well as customary regulatory approvals.

Whatman is a global supplier of filtration products and technologies, with a well-recognized brand and strong sector expertise. Whatman has a wide product range of filters and membranes for laboratory, research, life sciences, and medical technology applications. GE Healthcare's Life Sciences business is a leading provider of technologies for cellular and protein science research, and tools used in the manufacture of biopharmaceuticals such as vaccines, cell therapies, and antibodies. The strong strategic fit between the two businesses will offer substantial customer benefits and create significant synergies through complementary product and service offerings.

It is intended that the transaction will be implemented by way of a scheme of arrangement under UK law. The transaction has been recommended unanimously by the directors of Whatman, who have agreed to vote their shares in favor of the transaction. It is expected that the transaction will be completed in the second quarter of 2008.

GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurologic diseases, and other conditions earlier.

A global leader in filtration technology, Whatman provides innovative life-science products to the scientific community. Whatman has developed total sample preparation solutions through its robust line of filtration devices and membranes. The company's breakthrough protein array technology and FTA technology to capture archive and purify DNA at room temperature, enables it to provide novel solutions for the analytic, health care, and bioscience markets.


Related Links:
GE Healthcare
Whatman

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Nian Sun has spent years perfecting a device that he believes could change the way diseases are detected. (Photo courtesy of Alyssa Stone/Northeastern University)

Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air

Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more

Molecular Diagnostics

view channel
Image: At the MHH Institute of Human Genetics: Prof. Dr. Doris Steinemann, Dr. Bernardus Aldrige Allister and Prof. Dr Monika Golas (from left). (Image Credit: Karin Kaiser/MHH)

Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer

Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.